US 12,649,769 B2Granted

Recombinant human neuregulin derivatives and use thereof

AssigneeZensun (Shanghai) Science & Technology, Co., Ltd.

InventorMingdong Zhou

Life of this patent

Estimating the term…

Abstract

Disclosed is a use of recombinant human neuregulin derivatives in preparing a medicine for preventing, treating, or reducing the progression of cardiovascular diseases in mammals. In particular, the present invention relates to a novel recombinant human NRG-FC protein and a use thereof in the treatment of cardiovascular diseases. The protein has a prolonged half-life and enhanced biological activity.

Claims2

Dependent claims

A Neuregulin (NRG) fusion polypeptide comprising the amino acid sequence of SEQ ID NO:

2 or SEQ ID NO:
3.

Dependencies are inferred from the claim text.

Facts

Application: 17/642,855Filed 14 Sep 2020
Priority: CN 201910873003.916 Sep 2019
Published: US 2023/0057622 A123 Feb 2023
Granted: 9 Jun 2026
Term ends: Not estimatedThe source records don’t support an estimate.

Classification10 codes

A61P 9/04
Drugs for disorders of the cardiovascular system: inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
C07K 14/4756
Growth factors; Growth regulators: neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
A61P 9/00
Drugs for disorders of the cardiovascular system
C07K 14/55
Interleukins [IL]: il-2

Family

US 2023/0057622 A1Pre-grant publication · published 23 Feb 2023
US 12,649,769 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results